SECURITIES AND EXCHANGE COMMISSION

**SEC FORM 12-1 SRS**

SIMPLIFIED REGISTRATION STATEMENT FOR HOSPITALS

**GENERAL INSTRUCTIONS**

1. Pursuant to SEC Res. No. 225, s. of 2017, hospitals may use Form 12-1 SRS for registration of its securities that are sold or offered for sale pursuant to Section 8 and 12 of the Code. The use of Form 12-1 SRS is without prejudice to the right of the Commission to require such other information or documents as it may prescribe, consistent with the interest of the general public and for the protection of investors.
2. Under Section 13.1(b) of the Securities Regulation Code (“SRC”), the Commission may reject Registration Statement which on its face is *incomplete*. Notwithstanding the said provision, Sec. 14.2 of the SRC states that an amendment filed prior to the effectivity date of the Registration Statement (“RS”) shall recommence the twenty eight (28) day period within which the Commission shall act on a RS. Thus, should the company be amendable to extending the 28-day processing period (by executing a letter consenting to the processing time of the application to enable the company to amend its RS) the Market and Securities Regulation Department (“MSRD”) shall be constrained to elevate the application based on the existing RS on file, to enable MSRD to comply with the said processing period mandated under Section 12.6 of the SRC.
3. Attention is directed to Section 68, As Amended on the Financial Statement requirements. Prior to preparation of their filings, registrants should also review the provisions of SRC Rule 72.1, "General Rules and Regulations for Filing of SEC Forms with the Securities and Exchange Commission." Definitions contained in “Annex B” and SRC Rule 68, as amended, to the extent they are not defined herein, shall govern the meanings of similar terms used therein.
4. The registration statement shall be signed by the registrant’s chief executive officer, its chief operating officer, its chief financial officer, its controller, its chief accounting officer, its corporate secretary or persons performing similar functions.
5. The name of each person who signs the registration statement shall be typed or printed beneath his/her signature. Any person who occupies more than one of the specified position shall indicate the capacity in which he signs the registration statement. At least one (1) copy of the documents filed shall be manually signed and the unsigned copies shall be conformed.
6. Every amendment to a registration statement shall be signed by the persons specified in Section 12.4 of the Code or by any executive officer duly authorized by the Board of Directors. The final prospectus shall, however, be signed by all required signatories under Section 12.4 of the Code.
7. Three (3) copies of the complete Form 12-1 SRS shall be filed including exhibits and all other papers and documents filed as part thereof.
8. In case of withdrawal of a registration statement, fifty percent (50%) of the filing fee paid shall be *forfeited and not* be allowed for future application.
9. In the event that the registration statement is rejected pursuant to Section 13 of the Code, the filing fee paid thereon shall be *forfeited*.
10. Confidential Treatment of Information filed with the Commission –any request for confidentiality will be presented to Commission En Banc prior its application for registration or offering
11. How to use this form: Put ✓ inside the box to mark a box.

SECURITIES AND EXCHANGE COMMISSION

**SEC FORM 12-1 SRS**

SIMPLIFIED REGISTRATION STATEMENT FOR HOSPITALS

|  |  |
| --- | --- |
| 1. SEC Registration Number ……
 |  |
|  |
| 1. Exact name of issuer as specified in its charter ……………………………………………..
 |  |
|  |
| 1. Principal Business Address including postal code………..
 |  |
|  |
| 1. Province, country of other jurisdiction of incorporation or organization………..
 |  |
|  |
| 1. BIR Tax Identification No.
 |  |
|  |
| 1. Industry Group:
 | Hospitals and Physicians |
|  |
| 1. Telephone Number including area code:
 | Fax Number |
| (02) | (02) |
|  |
| 1. Official company’s website………..
 | www.  |
|  |
| 1. Fiscal Year (Day and Month)
 | 31 December |

**COMPUTATION OF FILING FEE**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Title of each class of securities to be registered | Amount to be registered | Proposed Maximum offering price per unit | Proposed maximum aggregate offering price | Amount of registration fee |
|  |  |  |  |  |

Registration Statements filed pursuant to Section 12 of the Code shall be accompanied by a fee as follows:

|  |  |
| --- | --- |
| Maximum aggregate price of securities to be offered | Amount of filing fee |
| Not more than P500 Million  | 0.10% of the maximum aggregate price of the securities to be offered |
| More than P500 Million but not more than P750 Million | P500,000 plus 0.075% of the excess over P500 Million |
| More than P750 Million but not more than P1 Billion | P687,500 plus 0.05% of the excess over P750 Million |
| More than P1 Billion | P812,500 plus 0.025% of the excess over P1 Billion  |

A legal research fee of 1% of the filing fee paid for filings made pursuant to SRC Rule 8.1 shall also be paid at the time of the filing.

**PART I - INFORMATION REQUIRED IN PROSPECTUS**

1. Front of the Registration Statement and Outside Front Cover Page of Prospectus
2. Inside Front Cover and First Two or More Pages of Prospectus
3. Forward looking Statement
4. Definition of Terms
5. Executive Summary
6. Risk Factors
7. Business Information
8. Use of Proceeds
9. Description of Securities Offered
10. Plan of Distribution
11. Capitalization
12. Outstanding Securities and Principal Shareholders
13. Board of Directors
14. Management
15. Financial Information
16. Information on Independent Accountant and Other Related Matters
17. Independent Auditors and Counsels
18. Other Material Factors

**PART II - INFORMATION REQUIRED IN REGISTRATION STATEMENT**

**BUT NOT REQUIRED IN PROSPECTUS**

1. Other Expenses of Issuance and Distribution

Give the itemized statement of all expenses of the offering other than the discounts and commission (if applicable). If any of the securities are registered for sale by security holders, state how much of the expenses the security holders will pay. If the amount of any items are not known, give estimates but identify them as such.

1. Exhibits

| **Description** | **Exhibit No.** |
| --- | --- |
| 1. Publication of Notice re: Filing
 |  |
| 1. Articles of Incorporation and By-laws
 |  |
| 1. Instruments defining the rights of security holders
 |  |
| 1. Opinion re: Legality
 |  |
| 1. Opinion re: Tax Matters
 |  |
| 1. Material Contracts
 |  |
| 1. Audited Financial Statements/Audited Interim Financial Statements
 |  |
| 1. Subsidiaries of the Issuer
 |  |
| 1. Consent of Experts and Independent Counsel
 |  |
| 1. Notarized Curriculum Vitae and Latest Photographs of Officers and Members of the Board of Directors
 |  |
| 1. Authorization re: Issuer’s Bank Account
 |  |
| 1. Copy of Board Resolution approving the securities offering and authorizing the filing of Registration Statement
 |  |
| 1. Duly verified resolution of the Issuer’s Board of Directors approving the disclosure contained in the registration statement and prospectus and assuming liability for the information contained therein
 |  |
| 1. Manual on Corporate Governance
 |  |
| 1. Additional Exhibits:
 |  |
| Certification that all mandated government license, permit are secured and valid |  |
| Certification on legal proceedings filed against and by the Issuer |  |
| Certification that all AFS of all subsidiaries has been filed with the Commission (if applicable) |  |
| Certification by selling shareholder as to the accuracy of any part of the registration statement contributed by such selling shareholders (if applicable) |  |
| Certification from Project Engineer as to percentage of building constructed |  |
| Tax Compliance Report filed by the Issuer  |  |
| Feasibility study prepared by qualified profession on the capacity of the Issuer to provide Medical Benefits |  |
| Memorandum of Agreement with other Group of Hospitals (if applicable) |  |
| Permit to Construct Hospital issued by Bureauof Health Facilitiesand Services (BHFS) of the Department of Health (DOH) |  |
| Credit Line Agreement |  |
| Copy of the Environmental Compliance Certificate |  |
| Copy of Development Agreement |  |
| Certified True Copy of Transfer Certificate Title |  |
|  |  |

1. Furnish any other document the omission of which will render the foregoing material facts or any other part of the Registration Statement misleading.

**SIGNATURES**

Pursuant to the requirements of the Securities Regulation Code, this registration statement is signed on behalf of the registrant by the undersigned, thereunto duly authorized, in the City of \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_on \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ .

|  |  |  |
| --- | --- | --- |
|  |  |  |
| Chief Operating Officer |  | Corporate Secretary |

|  |  |  |
| --- | --- | --- |
|  |  |  |
| Chief Executive Officer |  | Comptroller |

|  |  |  |
| --- | --- | --- |
|  |  |  |
| Chief Financial Officer |  | Chief Accounting Officer |

 **SUBSCRIBED AND SWORN** to before me this \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ affiants exhibiting to me his/her \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ as follows:

| Name | Type of Identification | I.D. Number | Date/Place of Issue |
| --- | --- | --- | --- |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

 **NOTARY PUBLIC**

Page No. \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Doc. No. \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Book No. \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Series of \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

(1) **Front of Registration Statement and Outside Front Cover Page of Prospectus.**

On the outside front cover page of the prospectus, the information provided shall be in an easily readable style and format and include, at a minimum, the following information:

(a) Name of the issuer

(b) The terms of the offer including:

 (i) Description and amount of securities offered;

(ii) Public offering price or the offering price range in the case of a preliminary prospectus;

(c) Name(s) of the salesman; (if applicable)

 (d) The date of the prospectus

(e) The following statement in bold face 12 point type, prominently displayed:

**A REGISTRATION STATEMENT RELATING TO THESE SECURITIES HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION, BUT HAS NOT YET BEEN DECLARED EFFECTIVE. NO OFFER TO BUY THE SECURITIES CAN BE ACCEPTED AND NO PART OF THE PURCHASE PRICE CAN BE RECEIVED UNTIL THE REGISTRATION STATEMENT HAS BECOME EFFECTIVE THEREBY, AND ANY SUCH OFFER MAY BE WITHDRAWN OR REVOKED, WITHOUT OBLIGATION OR COMMITMENT OF ANY KIND. AT ANY TIME PRIOR TO THE NOTICE OF ITS ACCEPTANCE AN INDICATION OF INTEREST IN RESPONSE THERETO INVOLVES NO OBLIGATION OR COMMITMENT OF ANY KIND. THIS PROSPECTUS SHALL NOT CONSTITUTE AN OFFER TO SELL OR BE CONSIDERED A SOLICITATION OF AN OFFER TO BUY.**

(2) **Inside Front Cover and First Two or More Pages of Prospectus.**

This (Preliminary/Final) Prospectus relates to the (primary/secondary) offer and sale of \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_common shares with an aggregate principal amount of \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_(Px.xx) of \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ (the “Company, the Issuer, or “Company Name) to be offered in \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_. The securities will be issued on \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_.

The \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_expects to raise gross proceeds amounting up to \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ and the net proceeds are estimated to be at least \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ after deducting fees, commissions and expenses relating to the issuance of the securities. The net proceeds of the Offer shall be used primarily by the Company to . For further detailed information on the use of proceeds, see “Use of Proceeds” on page \_\_\_\_\_\_\_\_\_\_\_ of this (preliminary/final) Prospectus.

Each investor must comply with all laws applicable to it and must obtain the necessary consent, approvals or permission for its purchase, offer or sale under the laws and regulation in force to which it is subject.

The company is organized under the Philippine Law. The Company is authorized to distribute dividends out of its surplus profit, in cash, properties of the Company, shares of stock. Dividends paid in the form of cash or property, are subject to approval of the Board of Directors of the Company. Dividends paid in the form of additional Common Shares are subject to the approval of the Board of Directors and stockholders who owns at least two-third (2/3) of the outstanding capital of the company. The Board may not declare dividends as determined by the Board, taking into consideration factors such as implementation of business plans, debt service requirements, operating expenses, budgets, funding of new investments and acquisitions and appropriate reserves and working capital. Refer to page \_\_\_\_ on Dividends and Dividend Policy of this Prospectus.

Unless otherwise, indicated, all information in this (Preliminary/Final) Prospectus is as of the date of this (Preliminary/Final) Prospectus. Neither the delivery of this (Preliminary/Final) Prospectus nor any sale made pursuant to this (Preliminary/Final) Prospectus shall, under any circumstances, create implication that the information contained herein is correct as of any date subsequent to the date hereof or that there has been no change in the affairs of the Company since such date.

No person has been authorized to give any information or to make any representation not contained in this (Preliminary/Final) Prospectus. If given or made, any such information or representation must not be relied upon as having been authorized by the Company. This (Preliminary/Final)Prospectus does not constitute an offer or any securities, or any offer to sell or solicitation of any offer to buy any of the securities of the Company in any jurisdiction, to or from any person to whom it is unlawful to make such offer or solicitation in such jurisdiction.

Before making an investment decision, investor must rely on their own due diligence examination of the Company and the terms of the Offer including the risks involved.

The Issuer has included in this Statement all of its representation about this offering. If anyone gives you more or different information, you should ignore it. You should carefully review and rely only on the information in this Statement in making an investment decision. The Investors should be aware that risks and uncertainties might occur.

By:

NAME & SIGNATUIRE

[Position]

**TABLE OF CONTENTS**

[Forward-looking Statements 1](#_Toc491770386)

[DEFINITION OF TERMS 2](#_Toc491770387)

[EXECUTIVE SUMMARY 2](#_Toc491770388)

[Brief Background on the Company 2](#_Toc491770389)

[Core Business 2](#_Toc491770390)

[Business Strategies 3](#_Toc491770391)

[RISK FACTORS 3](#_Toc491770392)

[BUSINESS INFORMATION 6](#_Toc491770393)

[Description of Business 6](#_Toc491770394)

[Competition 6](#_Toc491770395)

[Properties 7](#_Toc491770396)

[Legal Proceedings of Company, its Subsidiaries and/or Affiliates 7](#_Toc491770397)

[Services and Departments 8](#_Toc491770398)

[Transactions with and/or dependence on related parties 8](#_Toc491770399)

[USE OF PROCEEDS 9](#_Toc491770400)

[Net Proceeds 9](#_Toc491770401)

[Detailed Use of Net Proceeds 9](#_Toc491770402)

[DESCRIPTION OF SECURITIES OFFERED 11](#_Toc491770403)

[Securities of the Registrant 11](#_Toc491770404)

[Secondary Offering 11](#_Toc491770405)

[Recent sale of Unregistered or Exempt Securities 12](#_Toc491770406)

[Determination of the Offer Price 12](#_Toc491770407)

[Dilution 12](#_Toc491770408)

[Terms and Conditions of the Offer 13](#_Toc491770409)

[Management Discounts and/or Privileges 13](#_Toc491770410)

[Investor Restrictions 14](#_Toc491770411)

[PLAN OF DISTRIBUTION 14](#_Toc491770412)

[CAPITALIZATION 14](#_Toc491770413)

[Capital Stock 14](#_Toc491770414)

[OUTSTANDING SECURITIES AND PRINCIPAL SHAREHOLDERS 15](#_Toc491770415)

[Outstanding Securities 15](#_Toc491770416)

[Stockholders 15](#_Toc491770417)

[Dividends and Dividend Policy 17](#_Toc491770418)

[BOARD OF DIRECTORS 17](#_Toc491770419)

[Directors 17](#_Toc491770420)

[Business and Work Experience 17](#_Toc491770421)

[Security Ownership of Directors 18](#_Toc491770422)

[MANAGEMENT 19](#_Toc491770423)

[Officer, Manager and Key Person 19](#_Toc491770424)

[Security Ownership of Officers, Managers and Key Persons 19](#_Toc491770425)

[Compensation 20](#_Toc491770426)

[Arrangements with Officers, Directors, Managers and Key Persons 21](#_Toc491770427)

[Insolvency Legal Proceedings of Management and Key Personnel 21](#_Toc491770428)

[Certain Legal Proceedings 22](#_Toc491770429)

[Litigation 22](#_Toc491770430)

[Family Relationship 23](#_Toc491770431)

[Certain Relationship and Related Party Transactions 23](#_Toc491770432)

[FINANCIAL INFORMATION 23](#_Toc491770433)

[Management Discussion and Analysis (MD&A) or Plan of Operation 23](#_Toc491770434)

[Summary Financial Information 25](#_Toc491770435)

[Information on Independent Accountant and other Related Matters 26](#_Toc491770436)

[External Audit Fees and Services 26](#_Toc491770437)

[Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 27](#_Toc491770438)

[Taxation 27](#_Toc491770439)

[INDEPENDENT AUDITORS AND COUNSELS 27](#_Toc491770440)

[Tax and Legal Matters 27](#_Toc491770441)

[Independent Auditors 28](#_Toc491770442)

[OTHER MATERIAL FACTORS 28](#_Toc491770443)

# Forward-looking Statements

This Prospectus contains forward-looking statements that are, by their nature, subject to significant risks and uncertainties. These forward-looking statements include, without limitation, statements relating to:

* known and unknown risks;
* uncertainties and other factors which may cause actual results, performance or achievements of the Issuer , to be materially different from any future results; and
* performance or achievements expressed or implied by forward-looking statements.

Such forward-looking statements are based on assumptions regarding the present and future business strategies and the environment in which the registrant will operate in the future. Important factors that could cause some or all of the assumptions not to occur or cause actual results, performance or achievements to differ materially from those in the forward-looking statements include, among other things:

* the ability of the registrant to successfully implement its strategies;
* the ability of the registrant to anticipate and respond to healthcare trends;
* the ability of the registrant to successfully manage its growth;
* the condition and changes in the Philippines, Asian or global economies;
* any future political instability in the Philippines, Asia or other regions;
* changes in interest rates, inflation rates and the value of the Peso against the U.S. Dollar and other currencies;
* changes in government regulations, including tax laws, or licensing requirements in the Philippines, Asia or other regions; and
* competition in the healthcare industries in the Philippines and globally.

Additional factors that could cause actual results, performance or achievements of registrant to differ materially include, but are not limited to, those disclosed under “Risk Factors” and elsewhere in this Prospectus.

These forward-looking statements speak only as of the date of this Prospectus. The registrant expressly disclaim any obligation or undertaking to release, publicly or otherwise, any updates or revisions to any forward-looking statement contained herein to reflect any change in the expectations of the registrant with regard thereto or any change in events, conditions, assumptions or circumstances on which any statement is based.

This Prospectus includes forward-looking statements, including statements regarding the expectations and projections of the Issuer for future operating performance and business prospects. The words “believe”, “expect”, “anticipate”, “estimate”, “project”, “may”, “plan”, “intend”, “will”, “shall”, “should”, “would” and similar words identify forward-looking statements. In addition, all statements other than statements of historical facts included in this Prospectus are forward-looking statements. Statements in this Prospectus as to the opinions, beliefs and intentions of the Issuer accurately reflect in all material respects the opinions, beliefs and intentions of the management of the registrant as to such matters at the date of this Prospectus, although the Issuer can give no assurance that such opinions or beliefs will prove to be correct or that such intentions will not change. This Prospectus discloses, under the section “Risk Factors” and elsewhere, important factors that could cause actual results to differ materially from the expectation of the Issuer. All subsequent written and oral forward-looking statements attributable to either the Issuer or persons acting on behalf of the Issuer are expressly qualified in their entirety by cautionary statements

# DEFINITION OF TERMS

As used in this Prospectus, the following terms shall have the meanings ascribed to them:

|  |  |
| --- | --- |
| **“SEC”** | Philippine Securities and Exchange Commission |
| **“BIR”** | Bureau of Internal Revenue |
| **“DOH”** | Department of Health |
| **Environmental Compliance Certificate “ECC”** | Environmental Compliance Certificate is a document issued by the DENR/EMB after a positive review of an ECC application certifying that the proposed project will not cause significant negative environmental impact and the project proponent has complied with all the requirements of the Environmental Impact System, and has committed to implement its approved Environmental Management Plan |
| **Management Discount** |  |
|  |  |
|  |  |
|  |  |

# EXECUTIVE SUMMARY

The following summary is qualified in its entirety by, and should be read in conjunction with, the more detailed information and audited financial statements, including notes thereto, found in the appendices of this Prospectus.

Prospective investors should read this entire Prospectus fully and carefully, including the section on “Risk Factors”. In case of any inconsistency between this summary and the more detailed information in this Prospectus, then the more detailed portions, as the case may be, shall at all times prevail.

### Brief Background on the Company

|  |
| --- |
|  |

### Core Business

|  |
| --- |
|  |

### Business Strategies

|  |
| --- |
|  |

# RISK FACTORS

An investor should seek professional advice if he or she is uncertain of, or has not understood any aspect of the securities to invest in or the nature of risks involved in buying of securities.

An investor deals in an investment of which may carry a different level of risks.

1. The following is a summary of all the risks that apply to the Issuer and/or this offering. You should carefully consider these risks prior to investing in this offering.

**Operating History:**

The Issuer has limited or no operating history because the Issuer may have operated for only a short period of time, it has produced little or no profit. There is no assurance that it will ever produce a profit.

**Difficulty to collect from patients (select all that apply): Check Box**

|  |  |
| --- | --- |
|  | Existing law penalizes the refusal of hospitals and medical clinics to administer appropriate initial medical treatment and support in emergency or serious medical cases. |
|  | Hospital experience delay in payment from Health Insurance or Health Maintenance Organizations. |

However, the Issuer can mitigate said risk by:

|  |
| --- |
|  |

**Limited Resources/Losses (select all that apply):**

|  |  |
| --- | --- |
|  | The Issuer has limited resources and will not be able to continue operating without the proceeds from this offering. It is possible that the proceeds from this offering and other resources may not be sufficient for the Issuer to continue to finance operations. The Issuer expects to continue to experience losses from operations and it cannot be predicted when or if the Issuer will become profitable. If the Issuer achieves profitability, it may not be sustainable. |
|  | The Issuer has incurred losses since inception and may incur future losses. The Issuer has not yet generated a profit from operations. As of the date of the most recent financial statements, the Issuer had an accumulated deficit of  |

However, the Issuer can mitigate said risk by:

|  |
| --- |
|  |

**Key Personnel**

|  |  |
| --- | --- |
|  | The Issuer success depends substantially on the services of a small number of individuals |
|  | The Issuer may be harmed if it loses the services of these people and it is not able to attract and retain qualified replacements |
|  | The Issuer’s officers, directors, managers and key persons will continue to have substantial ownership and control over the Issuer after the offering |
|  | The Issuer does not maintain key person life insurance on those individuals on whom the Issuer’s success depends. The loss of any of these individuals could have a substantial negative impact on the Issuer and your investments. |

However, the Issuer can mitigate said risk by:

|  |
| --- |
|  |

**Inexperience Management (select all that apply):**

|  |  |
| --- | --- |
|  | None of the Issuer’s officers, directors, and/or managers has managed a company in this industry. The Issuer’s ability to operate successfully may depend on its ability to attract and retain qualified personnel, who may be in great demand. |
|  | None of the Issuer’s officers, directors, and/or managers has experience in managing a development stage hospital |

However, the Issuer can mitigate said risk by:

|  |
| --- |
|  |

**Past Failures**

|  |  |
| --- | --- |
|  | Prior to organizing the Issuer, one or more of the Issuer’s officers, directors, and/or managers operated a business in which shareholders lost part or all of their investment. The Issuer’s ability to operate successfully may depend on its officers, directors, and/or managers to succeed where they have failed before. |

However, the Issuer can mitigate said risk by:

|  |
| --- |
|  |

**Government Regulations:**

The Issuer must comply with local and national rules and regulations. If the Issuer fails to comply with a rule or regulation it may be subject to fines or other penalties, or its permit or license may be revoked or suspended. The Issuer may have to stop operation and you may lose your entire investment.

**Dilution** (select all that apply):

|  |  |
| --- | --- |
|  | The price of a share in this offering is significantly higher than the book value of the securities. By participating in this offering, you will incur immediate and substantial dilution of the book value of your investment. |
|  | To the extent outstanding options or warrants to purchase securities are exercised, new Investors will incur further dilution of the book value of their investment |
|  | There are no limits in place to restrict the Issuer’s ability to issue securities in the future. If the Issuer issues additional securities, by participating in this offering you may experience further dilution of the value of your investment. |

**No Existing Market**

|  |  |
| --- | --- |
|  | Because there is no market for the Issuer’s securities, you may not be able to sell your securities or recover any part of your investment. You should not invest unless you can afford to hold your investment indefinitely. |

**Offering Price**

|  |  |
| --- | --- |
|  | The offering price of the Issuer’s securities has been arbitrarily set and accordingly should not be considered an indication of the actual value of the Issuer. |

**Best-effort Offering:**

|  |  |
| --- | --- |
|  | The Issuer is offering these securities on a “best-effort” basis. The Issuer has not contracted with an underwriter, placement agent, or other person to purchase or sell all, or a portion of its securities and there is no assurance that it can sell all or any of the securities. |

**Lack of Investor Control (select if applicable):**

|  |  |
| --- | --- |
|  | The Issuer’s officers, directors, managers, and/or key persons will continue to have substantial control over the Issuer after the offering. As such, you may have little or no ability to influence the affairs of the Issuer.  |

**Other Risks**

|  |
| --- |
| Risk relating to Hospital Business* Licenses, permits
* Regulatory risks
* Healthcare infections
* Emergencies/disaster risks
* Government discount programs/collection from Philhealth
* Hazardous material events, e.g. chemical/radiological exposure
* Physician litigation

Risks to purchasers associated with corporate actions including:• Additional issuance of securities• Issuer repurchases of securities• A sale of the Issuer or of assets of the Issuers• Transactions with related partiesDescribe any other risks that apply to the Issuer and/or the offering that have not yet been address above. Failure to disclose all material risks may subject the Issuer, its Officers, Directors, Managers or promoters to liability for securities fraud. |

# BUSINESS INFORMATION

### Description of Business

1. Business of the Issuer and form of organization

|  |
| --- |
| Describe in details the business of the Issuer |

1. Anticipated Business Plan of the Issuer

|  |
| --- |
| Describe in detail the Anticipated Business Plan of the Issuer |

1. Operations

The Issuer (select all that apply):

|  |  |
| --- | --- |
|  | Has never conducted operations |
|  | Is in the construction development stage |
|  | Is currently conducting operations |
|  | Has shown a profit in the last fiscal year |

|  |
| --- |
| Briefly describe |

1. Jurisdiction: Is the Issuer an entity organized and doing business in the Philippines?

\_\_\_\_\_Yes\_\_\_\_\_ No

1. Date of Incorporation: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
2. Fiscal Year End (Month and Day):

### Competition

|  |
| --- |
| Describe the competition that the Issuer faces, and how the Issuer intends to compete. If the Issuer offers what it considers to be unique good or services, discuss competition from companies that provide similar or substantial goods or services. Name the Issuer’s principal competitors, and indicate their relative size and financial market strengths. Describe the Issuer’s strategy, whether to compete by price, service, or some other basis |

**Employees**

The Issuer (select all that apply):

|  |  |
| --- | --- |
|  | Has existing Labor Union in the company |
|  | Has existing Collective Bargaining Agreement |
|  | Has existing labor strike |

|  |
| --- |
| Indicate whether or not any of them are subject to collective bargaining agreements (CBA) and the expiration dates of any CBA. If the registrant’s employees are on strike, or have been in the past three (3) years, or are threatening to strike, describe the dispute. Indicate any supplemental benefits or incentive arrangements the registrant has or will have with its employees; |

|  |  |  |
| --- | --- | --- |
| Type of Employees | Number of CurrentEmployees | Expected within the Next 12 months |
| Medical Support Staff |  |  |
| Administrative Staff |  |  |
| Engineering and Maintenance |  |  |
| Outsourced |  |  |
| Clerical |  |  |
| Others |  |  |

**Medical Practitioners**

|  |
| --- |
| Briefly describe the qualifications and criteria to qualify. Disclose the current number of medical practitioners and its expected number within the next 12 months. |

### Properties

The Issuer (select all that apply):

|  |  |  |
| --- | --- | --- |
| **Property** | Own | Lease |
| Land/Building/Real Estate |  |  |
| Equipment and other long term assets |  |  |
| Intangible property such as patents, licenses, copyrights, trademarks, etc. |  |  |

|  |
| --- |
| Give the location and describe the condition of the principal properties (such as real estate, plant and equipment, mines, patents, etc.) that the registrant and its subsidiaries own. Disclose any mortgage, lien or encumbrance over the property and describe the limitations on ownership or usage over the same. Indicate also what properties it leases, the amount of lease payments, expiration dates and the terms of renewal options. Indicate what properties the registrant intends to acquire in the next twelve (12) months, the cost of such acquisitions, the mode of acquisition (i.e. by purchase, lease or otherwise) and the sources of financing it expects to use. If the property is being leased, indicate and describe the terms and conditions of the lease. |

### Legal Proceedings of Company, its Subsidiaries and/or Affiliates

|  |
| --- |
| Describe briefly any material pending legal proceedings to which the registrant or any of its subsidiaries or affiliates is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities or any other entity. |

|  |
| --- |
|  |

### Services and Departments

|  |
| --- |
| Provide information on hospital departments and their functions. Include personnel overview per department and their functions. |

### Transactions with and/or dependence on related parties

|  |
| --- |
|  |

# USE OF PROCEEDS

### Net Proceeds

1. The net proceeds of the offering for the minimum and maximum offering amounts are as follows:

|  | Minimum Offering | Maximum Offering |
| --- | --- | --- |
| **Gross Proceeds from the Offering** |  |  |
| Less: Expenses |  |  |
|  SEC Registration Fee |  |  |
|  UP Legal Research Fee |  |  |
|  Documentary Stamp |  |  |
|  Legal Fees |  |  |
|  Auditors Fees |  |  |
|  Others (Specify) |  |  |
|  |  |  |
| **Net Proceeds from the Offering** |  |  |

### Detailed Use of Net Proceeds

Provide a detailed breakdown on how the Issuer intends to use the net offering proceeds. Include the repayment of debt, payment to officers, directors and related parties and any purchase of assets.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Description of Use | Minimum Offering | % | Maximum Offering | % |
| Amount | Amount |
|  |  |  |  |  |
|  |  |  |  |  |
| **T O T A L** |  |  |  |  |

Where less than all of the securities to be offered may be sold and more than one use is listed for the proceeds, the registrant shall indicate the order of priority of such purposes and discuss its plans if substantially less than the maximum proceeds are obtained.

If any material amounts of other funds are necessary to accomplish the specified purpose(s) for which the offering is made, the registrant shall state the amounts and sources of such other funds needed.

If the proceeds will be used to pay-off existing debt, disclose the following: \_\_\_\_\_\_ Not Applicable

| Name of Debtor | Amount of Debt | Interest | Maturity Date |
| --- | --- | --- | --- |
|  |  |  |  |
|  |  |  |  |
| **T O T A L** |  |  |  |

|  |
| --- |
| Description of the debt |

Is the debtor related to the Issuer or any of its Directors or Officers?\_\_\_\_\_Yes \_\_\_\_\_No

|  |
| --- |
| If the answer to any of the above is "yes", disclose the relationship between each person and the issuer and the principal terms of each transaction. If assets were acquired from a person, disclose the cost of the asset to the issuer and the method used to determine this cost. Disclose for each person who has been involved in more than one related party transaction, their relationship with the issuer and which of the transactions they have been involved with. |

Is the proceeds will be used to purchase real estate property? \_\_\_\_\_\_\_\_\_Yes \_\_\_\_\_No

 (Provide information on each property acquired)

|  |  |
| --- | --- |
| Description of Property |  |
| Name of Seller |  |
| Acquisition Cost |  |
| Terms of Payment |  |

|  |
| --- |
| If the answer to any of the above is "yes", disclose the relationship between each person and the issuer and the principal terms of each transaction. If assets were acquired from a person, disclose the cost of the asset to the issuer and the method used to determine this cost. Disclose for each person who has been involved in more than one related party transaction, their relationship with the issuer and which of the transactions they have been involved with. |

If any material amount of the proceeds is to be used to acquire assets or finance the acquisitions of other businesses, describe the assets or businesses and identify the persons from whom they will be bought. State the cost of the assets and, where such assets are to be acquired from affiliates of the registrant or their associates, give the names of the persons from whom they are to be acquired and set forth the principle followed in determining the cost to the registrant.

If the proceeds will be used for the construction of the hospital, provide the following:

| Project Name |  |
| --- | --- |
| Project Cost (Estimate) |  |
| Schedule of Disbursement |  |
| Target Completion Date |  |
| Percentage Completed |  |

1. If proceeds to this offering is not sufficient to fund the intended use, where will the company source the additional funding? \_\_\_\_\_ Not Applicable

|  |
| --- |
|  |

# DESCRIPTION OF SECURITIES OFFERED

### Securities of the Registrant

1. The securities being offered are (select all that apply):

|  |  |
| --- | --- |
|  | Founder’s Shares |
|  | Common Shares |
|  | Preferred Shares |
|  | Others (specify): |

|  |
| --- |
| 1. State the amount of capital stock of each class issued or included in the shares of stock to be offered:

(b) If the registrant is offering com mon equity, describe any dividend, voting and preemption rights.(c) If the registrant is offering preferred stock, describe the dividend, voting, conversion and liquidation rights as well as redemption or sinking fund provisions. |

1. These securities have (select all that apply):

|  |  |
| --- | --- |
|  | Cumulative voting rights |
|  | Pre-emptive rights to purchase any new issue of securities |
|  | Preference as to dividends or interest |
|  | Restrictions on dividends or other distributions |
|  | Preference over liquidation |
|  | Anti-dilution |
|  | Conversion rights |
|  | Other special voting rights |
|  | Other special rights or preference (specify): |
| (a) Describe any other material rights of common or preferred stockholders.(b) Describe any provision in the charter or by-laws that would delay, defer or prevent a change in control of the registrant. |

1. Source of the aforementioned shares offered for sale (select all that apply):

|  |  |
| --- | --- |
|  | Primary (from the unissued portion of the Authorized Capital Stock) |
|  | Secondary Selling Shareholders |

|  |
| --- |
|  |

### Secondary Offering

1. If any of the securities to be registered are to be offered for the account of shareholder, name each such security holder, indicating the following: \_\_\_\_\_ Not Applicable

| Name of Selling Shareholder | Class of Securities Offered | No. of Shares Offered for Sale | Offer Price | Issue Value |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |

1. The selling shareholder/s (select all that apply):

|  |  |
| --- | --- |
|  | Certifies as to the accuracy of any part of the registration statement contributed to |
|  | Certifies that he/she are the legitimate beneficial owner of the securities. |

1. Are these securities are to be registered under a delay or continuous offering?

\_\_\_\_\_\_Yes \_\_\_\_\_\_\_No

### Recent sale of Unregistered or Exempt Securities

|  |
| --- |
| Furnish the following information as to all securities of the registrant sold by it within the past three (3) years which were not registered under the Code. Include sales of reacquired securities, as well as new issues, securities issued in exchange for property, services, or other securities, and new securities resulting from the modification of outstanding securities. Indicate whether the issuer received written confirmation from the Commission under SRC Rule 10.1 that such exemptive relief from registration was available and, if so, the date such confirmation was issued: |

|  |  |  |  |
| --- | --- | --- | --- |
| Class of Securities Sold | Purchasers | Consideration | Exemption from Registration Claimed |
|  |  |  |  |
|  |  |  |  |

### Determination of the Offer Price

|  |
| --- |
| Discuss the various factors considered in determining the offering price of the securities for registration. The following factors may be relevant to the price at which the securities are being offered: after-tax earnings, price/earnings multiple, net tangible bookvalue per share.  |

### Dilution

|  |
| --- |
| Where common equity securities are being registered and there is a substantial disparity between the public offering price and the effective cash cost to officers, directors, promoters and affiliated persons of common equity acquired by them in transactions during the past five (5) years, or which they have the right to acquire, and the registrant is not subject to the reporting requirements of Section 17 of the Code immediately prior to filing of the registration statement, there shall be included a comparison of the public contribution under the proposed public offering and the effective cash contribution of such persons. In such cases, and where common equity securities are being registered by a registrant that has had losses in each of its last three fiscal years, or from inception if shorter, and there is a material dilution of the purchasers' equity interest, the following shall be disclosed: (1) The net tangible book value per share before and after the distribution. For this purpose, net tangible book value means total assets (exclusive of copyrights, patents, goodwill, research and development costs, pre-operating costs, and similar intangible assets) minus total liabilities. (2) The amount of the increase in such net tangible book value per share attributable to the cash payments made by purchasers of the shares being offered; and(3) The amount of the immediate dilution from the public offering price which will be absorbed by such purchasers. |

The following does not purport to be a complete listing of all the rights, obligations, and privileges attaching to or arising from the Offer Shares. Some rights, obligations, or privileges may be further limited or restricted by other documents and subject to final documentation. Prospective investors are enjoined to perform their own independent investigation and analysis of the Company and the Offer Shares. Each prospective investor must rely on its own appraisal of the Company and the Offer Shares and its own independent verification of the information contained herein and any other investigation it may deem appropriate for the purpose of determining whether to invest in the Offer Shares and must not rely solely on any statement or the significance, adequacy, or accuracy of any information contained herein. The information and data contained herein are not a substitute for the prospective investor’s independent evaluation and analysis.

### Terms and Conditions of the Offer

|  |  |
| --- | --- |
| Issue Size …………………………………….. |  |
| Offer Shares ………………………………… |  |
| Terms and Manner of Payment …….. |  |
| Offer Period …………………………………. |  |
| Applications …………………………………. |  |
| Eligible Applicants ………………………., |  |
| Restriction on Ownership ……………., |  |
| Right to accept, reject and scale down applications ……………………….. |  |
| Refunds ………………………………………. |  |
| Issuance and Transfer of Taxes ……. |  |
| Restrictions on the Issuance and Disposal of shares ……………………….. |  |
| Trading of Shares ………………………… |  |

### Management Discounts and/or Privileges

1. Does the company provide discounts and/or privileges to its medical and non-medical stockholders?

|  |
| --- |
| Disclose in details the discounts and/or privileges |

### Investor Restrictions

1. Is the offering subject to any other Investor restrictions? \_\_\_\_\_ Yes \_\_\_\_\_ No

|  |
| --- |
|  |

1. Are the securities subject to any resale restrictions by the Issuer? \_\_\_\_\_ Yes \_\_\_\_\_ No

|  |
| --- |
|  |

# PLAN OF DISTRIBUTION

1. List the persons or companies who will offer and sell the securities on behalf of the Issuer:

| Name | Relationship to Issuer | Address | Tel. No. | Compensation received for selling securities |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |

Outline briefly the plan of distribution of any securities to be registered.

# CAPITALIZATION

### Capital Stock

|  |
| --- |
|  |

# OUTSTANDING SECURITIES AND PRINCIPAL SHAREHOLDERS

### Outstanding Securities

1. For each class of the Issuer’s securities, indicate the total number of outstanding securities and the total number of securities of the Issuer is authorized to issue. Also, include a description of each class of securities.

| Class of Securities | Securities Outstanding | Securities the Issuer is Authorized to Issue |
| --- | --- | --- |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
| **T O T A L** |  |  |

### Stockholders

Original Stockholders

1. Provide the names of the original stockholders, class of securities, number of shares held and percentage of total shares held over outstanding shares.

| No | Name | Class of Securities | Shares Held | % |
| --- | --- | --- | --- | --- |
| 1 |  |  |  |  |
| 2 |  |  |  |  |
| 3 |  |  |  |  |
| 4 |  |  |  |  |
| 5 |  |  |  |  |
| 6 |  |  |  |  |
| 7 |  |  |  |  |
| 8 |  |  |  |  |
|  | **T O T A L** |  |  |  |

Current Stockholders

1. Provide the names of the current stockholders, class of securities, number of shares held and percentage of total shares held over outstanding shares. \_\_\_\_ Same as Above

| No | Name | Class of Securities | Shares Held | % |
| --- | --- | --- | --- | --- |
| 1 |  |  |  |  |
| 2 |  |  |  |  |
| 3 |  |  |  |  |
| 4 |  |  |  |  |
|  | **T O T A L** |  |  |  |

Top 20 Stockholders

1. Provide the names of the Top Twenty (20) principal shareholders who beneficially owns at least 10% interest of each class of securities in the Issuer.

| No | Name | Class of Securities | Number of Share Held | % |
| --- | --- | --- | --- | --- |
| 1 |  |  |  |  |
| 2 |  |  |  |  |
| 3 |  |  |  |  |
| 4 |  |  |  |  |
| 5 |  |  |  |  |
| 6 |  |  |  |  |
| 7 |  |  |  |  |
| 8 |  |  |  |  |
| 9 |  |  |  |  |
| 10 |  |  |  |  |
| 11 |  |  |  |  |
| 12 |  |  |  |  |
| 13 |  |  |  |  |
| 14 |  |  |  |  |
| 15 |  |  |  |  |
| 16 |  |  |  |  |
| 17 |  |  |  |  |
| 18 |  |  |  |  |
| 19 |  |  |  |  |
| 20 |  |  |  |  |
|  | **T O T A L** |  |  |  |

### Dividends and Dividend Policy

1. Dividends and Dividend Policy

|  |
| --- |
| (a) Discuss any cash dividends declared on each class of its common equity by the registrant for the two most recent fiscal years and any subsequent interim period for which financial statements are required to be presented by SRC Rule 68 if applicable.1. Describe any restriction that limits the ability to pay dividends on common equity or that are likely to do so in the future.
2. Describe company’s dividend policy
 |

# BOARD OF DIRECTORS

### Directors

1. The table below sets forth each member of the Board of Directors of the Issuer as of the date of the Prospectus:

| No | Name | Age | Position | Citizenship | Year Appointed |
| --- | --- | --- | --- | --- | --- |
| 1 |  |  | Chairman | Filipino |  |
| 2 |  |  | Vice Chairman | Filipino |  |
| 3 |  |  | Director | Filipino |  |
| 4 |  |  | Director | Filipino |  |
| 5 |  |  | Director | Filipino |  |
| 6 |  |  | Director | Filipino |  |
| 7 |  |  | Director | Filipino |  |
| 8 |  |  | Director | Filipino |  |
| 9 |  |  | Director | Filipino |  |
| 10 |  |  | Director | Filipino |  |
| 11 |  |  | Director | Filipino |  |
| 12 |  |  | Director | Filipino |  |
| 13 |  |  | Independent Director | Filipino |  |
| 14 |  |  | Independent Director | Filipino |  |
| 15 |  |  | Independent Director | Filipino |  |

### Business and Work Experience

1. Provide information on the business and/or professional working experience of the above named Directors for the past five (5) years:

| No | Name | Business and/or Professional Work Experience |
| --- | --- | --- |
| 1 |  |  |
| 2 |  |  |
| 3 |  |  |
| 4 |  |  |
| 5 |  |  |
| 6 |  |  |
| 7 |  |  |
| 8 |  |  |
| 9 |  |  |
| 10 |  |  |
| 11 |  |  |
| 12 |  |  |
| 13 |  |  |
| 14 |  |  |
| 15 |  |  |

1. Other Directorship of Independent Directors

| Name of Independent Director | Reporting Company | Year Appointed |
| --- | --- | --- |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |

### Security Ownership of Directors

The following table shows the security ownership of directors in the common shares of the Company as of\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Name | Amount and Nature of Beneficial Ownership | Citizenship | No. of Shares | % Ownership |
| Direct | Indirect |
|  |  |  | Filipino |  |  |
|  |  |  | Filipino |  |  |
|  |  |  | Filipino |  |  |
|  |  |  | Filipino |  |  |
|  |  |  | Filipino |  |  |
|  |  |  | Filipino |  |  |
|  |  |  | Filipino |  |  |
|  |  |  | Filipino |  |  |
|  |  |  | Filipino |  |  |
|  |  |  | Filipino |  |  |
|  |  |  | Filipino |  |  |
|  |  |  | Filipino |  |  |
|  |  |  | Filipino |  |  |
|  |  |  | Filipino |  |  |
|  |  |  | Filipino |  |  |

# MANAGEMENT

### Officer, Manager and Key Person

1. Provide background information for each Officer, Manager and Key Person. The term “Key Person” means a person who makes significant contribution to the business of the Issuer.

|  |  |
| --- | --- |
| Name |  |
| Age |  |
| Title |  |
| Time spent on Issuer’s business | (Indicate if Part Time or Full Time) |
| Hospital affiliation – 5 years |  |
| Education |  |

|  |  |
| --- | --- |
| Name |  |
| Age |  |
| Title |  |
| Time spent on Issuer’s business | (Indicate if Part Time or Full Time) |
| Hospital affiliation – 5 years |  |
| Education |  |

|  |  |
| --- | --- |
| Name |  |
| Age |  |
| Title |  |
| Time spent on Issuer’s business | (Indicate if Part Time or Full Time) |
| Hospital affiliation – 5 years |  |
| Education |  |

### Security Ownership of Officers, Managers and Key Persons

The following table shows the security ownership of management in the common shares of the Company as of \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Name** | **Amount and Nature of Beneficial Ownership** | **Citizenship** | **No. of Shares** | **% Ownership** |
| **Direct** | **Indirect** |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |

### Compensation

1. List the compensation paid by the Issuer to the Chief Executive Officers and four (4) most highly compensated officers other than the CEO, all of whom shall be individually named during the last fiscal year:

**SUMMARY COMPENSATION TABLE**

Annual Compensation

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

 (a) (b) (c) (d) (e)

 Name and Other Annual

 Principal position Year Salary (P) Bonus (P) Compensation

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

CEO \_\_\_\_\_

 \_\_\_\_\_

A \_\_\_\_\_\_

 \_\_\_\_\_\_

B \_\_\_\_\_\_

 \_\_\_\_\_\_

C \_\_\_\_\_\_

 \_\_\_\_\_\_

D \_\_\_\_\_\_

E All other officers and

 directors as a

 group unnamed

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. The Issuer (select all that apply):

|  |  |
| --- | --- |
|  | Expects compensation to change in the next year |
|  | Owes compensation for prior years |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Arrangements with Officers, Directors, Managers and Key Persons1. The Issuer (select all that apply):

|  |  |
| --- | --- |
|  | Has entered into employment or non-compete agreements with any Officer, Manager, Director or Key Person. |
|  | Plans to enter into employment or non-compete agreements with any Officer, Manager, Director or Key Person |

 |

### Insolvency Legal Proceedings of Management and Key Personnel

1. An Officer, Manager, Director, Key Person of the Issuer (Put ✓ in column if applicable and х otherwise):

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Name** | **Position:****D = Director****ID – Independent Director****O - Officer** | **Civil** | **Criminal** | **Administra-tive** | **Bankruptcy** | **Case Details** |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |

### Certain Legal Proceedings

This section applies to:

* The issuer, its subsidiaries and affiliates
* All Directors and Officers of the Issuer
* All Beneficial Owners of 10% or more of the Issuer’s outstanding voting equity and
* All Promoters of the Issuers
1. Have any of the above-listed persons filed or subject of any bankruptcy petition filed by or against any business of which such person was a general partner or executive either at the time of the bankruptcy or within two (2) years prior to that time. [ ] Yes [ ] No

|  |
| --- |
|  |

1. Have any of the above-listed persons been named as the subject of a pending felony or misdemeanor criminal proceeding excluding traffic violations or other minor offenses not related to fraud or a financial crime? [ ] Yes [ ] No

|  |
| --- |
|  |

1. Have any of the above-listed persons been the subject of an order, judgment, decree, sanction or administrative findings imposed by any government agency, administrative agency, self-regulatory organization, civil court, or administrative court in the last five (5) years related to his or her involvement in any type of business, securities, insurance, or banking activity? ? [ ] Yes [ ] No

|  |
| --- |
|  |

1. Are any of the above-listed persons the subject of a pending civil, administrative, or self-regulatory action related to his or her involvement in any type of business, securities, insurance, or banking activity? ? [ ] Yes [ ] No

|  |
| --- |
|  |

1. Has any civil action, administrative proceeding, or self-regulatory proceeding been threatened against any of the above-listed persons related to his or her involvement in any type of business, securities, insurance or banking activity? [ ] Yes [ ] No

|  |
| --- |
|  |

### Litigation

1. The Issuer (select all that apply):

|  |  |
| --- | --- |
|  | Has been involved in litigation or subject to administrative action in the last five (5) years that has had a material effect upon the Issuer’s business, financial condition or operations |
|  | Has pending litigation or administrative action that may have a material effect upon the Issuer’s business, financial condition, or operations |
|  | Is currently threatened by litigation or administrative action that may have a material effect upon the Issuer’s business, financial condition, or operations |
|  | None of the above |

|  |
| --- |
|  |

### Family Relationship

1. Describe any family relationships up to the fourth civil degree either by consanguinity or affinity among directors, executive officers, or persons nominated or chosen by the registrant to become directors or executive officers.

|  |
| --- |
|  |

### Certain Relationship and Related Party Transactions

1. The Issuer (select all that apply):

|  |  |
| --- | --- |
|  | Has made loans to an Officer, Manager, Director or Principal Stockholders within the last two (2) years |
|  | Has one or more outstanding loans with an Officer, Manager, Director or Principal Stockholder in the future. |
|  | Has done other business not associated with this offer with current Officer, Manager, Director, or Principal Stockholder within the last two (2) years  |
|  | Plans to do other business not associated with this offering with a current Officer, Manager, Director, or Principal Stockholder in the future |

# FINANCIAL INFORMATION

### Management Discussion and Analysis (MD&A) or Plan of Operation

|  |
| --- |
| Registrants that have not had revenues from operations in each of the last two fiscal years, or the last fiscal year and any interim period in the current fiscal year for which financial statements are furnished in the disclosure document, shall in addition to applicable items under subparagraph (2), provide the information in subparagraph (1) hereof. (1) Plan of OperationDescribe the plan of operation for the next twelve (12) months. This description should include such matters as:(a) a discussion of how long the registrant can satisfy its cash requirements and whether it will have to raise additional funds in the next twelve (12) months;(b) a summary of any product research and development that the registrant will perform for the term of the plan;(c) any expected purchase or sale of plant and significant equipment; and(d) any expected significant changes in the number of employees.1. Management’s Discussion and Analysis

MD&A helps explain financial results. A reader of the MD&A should understand the financial results of the registrant’s business as discussed in the “Business” section. It shall provide information with respect to liquidity, capital resources and other information necessary to understanding the registrant’s financial condition and results of operation. The discussion and analysis shall focus specifically on material events and uncertainties known to management that would cause reported financial information not to be necessarily indicative of future operating results or of future financial condition. This would include descriptions and amounts of matters that would have an impact on future operations and have not had an impact in the past, and matters that have had an impact on reported operations and are not expected to have an impact upon future operations.  For both full fiscal years and interim periods, disclose the company’s and its majority-owned subsidiaries’ top five (5) key performance indicators. It shall include a discussion of the manner by which the company calculates or identifies the indicators presented on a comparable basis.(a) Full fiscal yearsDiscuss the registrant's financial condition, changes in financial condition and results of operations for each of the last three fiscal years. If the registrant’s financial statement shows losses from operations, explain the causes of these losses and the steps the registrant has taken or is taking to address these causes. This discussion should address the past and future financial condition and results of operation of the registrant, with particular emphasis on the prospects for the future. The discussion should also address those key variable and other qualitative and quantitative factors which are necessary to an understanding and evaluation of the registrant. If material, the registrant should disclose the following:(i) Any known trends or any known demands, commitments, events or uncertainties that will result in or that are reasonably likely to result in the registrant’s liquidity increasing or decreasing in any material way. The registrant shall indicate balance sheet conditions or income or cash flow items that it believes may be indicators of its liquidity condition. The following conditions shall be indicated: whether or not the registrant is having or anticipates having within the next twelve (12) months any cash flow or liquidity problems; whether or not the registrant is in default or breach of any note, loan, lease or other indebtedness or financing arrangement requiring it to make payments; whether or not a significant amount of the registrant’s trade payables have not been paid within the stated trade terms. If a material deficiency is identified, the course of action that the registrant has taken or proposes to take to remedy the deficiency should also be indicated. The registrant should identify and separately describe internal and external sources of liquidity, and briefly discuss any sources of liquid assets used.  The term “liquidity” refers to the ability of an enterprise to generate adequate amount of cash to meet its needs for cash. Liquidity generally must be discussed on both a long-term and short-term basis. 1. Any events that will trigger direct or contingent financial obligation that is material to the company, including any default or acceleration of an obligation;

(iii) All material off-balance sheet transactions, arrangements, obligations (including contingent obligations), and other relationships of the company with unconsolidated entities or other persons created during the reporting period. (iv) Any material commitments for capital expenditures, the general purpose of such commitments, and the expected sources of funds for such expenditures should be described;(v) Any known trends, events or uncertainties that have had or that are reasonably expected to have a material favorable or unfavorable impact on net sales or revenues or income from continuing operations should be described. If the registrant knows of events that will cause material change in the relationship between costs and revenues (such as known future increases in cost of labor or materials or price increases or inventory adjustments), the change in the relationship shall be disclosed. (vi) Any significant elements of income or loss that did not arise from the registrant's continuing operations;(vii) The causes for any material change from period to period which shall include vertical and horizontal analyses of any material item; The term “material” in this section shall refer to changes or items amounting to five percent (5%) of the relevant accounts or such lower amount, which the registrant deems material on the basis of other factors.(viii) Any seasonal aspects that had a material effect on the financial condition or results of operations.  (b) Interim Periods If interim financial statements are included in the registration statement or report, provide a comparable discussion that will enable the reader to assess material changes in financial condition and results of operations since the end of the last fiscal year and for the comparable interim period in the preceding year.  |

### Summary Financial Information

Prospective purchasers of the Offer should read the summary financial data below together with the financial statements, including the notes thereto, included in this Prospectus and “Management's Discussion and Analysis of Results of Operations and Financial Condition”. The summary financial data for the \_\_\_\_\_\_\_\_\_ year ended \_\_\_\_\_\_\_\_\_\_\_ and \_\_\_\_\_\_\_\_ are derived from the audited financial statements of \_\_\_\_\_\_\_\_\_\_\_\_\_, including the notes thereto. The detailed financial information for the \_\_\_\_\_\_\_ years ended \_\_\_\_\_\_\_\_ are found on page \_\_\_\_\_\_\_\_ Prospectus and the \_\_\_\_\_\_\_ months ended \_\_\_\_\_\_\_\_\_\_\_\_\_ are found on page \_\_\_\_\_\_\_ Prospectus.

The summary of financial and operating information of \_\_\_\_\_\_\_\_\_\_\_ presented below as of and for the years ended \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ were derived from the consolidated financial statements of \_\_\_\_\_\_\_\_\_\_\_, audited by \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_and prepared in compliance with the Philippine Financial Reporting Standards (“PFRS”). The financial and operating information of \_\_\_\_\_\_\_\_\_\_\_ presented below as of and for the \_\_\_\_\_\_\_months ended \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ were derived from the unaudited consolidated financial statements of \_\_\_\_\_\_\_\_\_ prepared in compliance with Philippine Accounting Standards (“PAS”) 34, “Interim Financial Reporting” and reviewed by \_\_\_\_\_\_\_\_\_\_\_\_\_\_. in accordance with Philippine Standards on Reviewing Engagements (“PSRE”) 2410, “Review of Interim Financial Information performed by the Independent Auditors of the Entity.” The information below should be read in conjunction with the consolidated financial statements of \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ and the related notes thereto, which are included in \_\_\_\_\_\_\_\_\_\_\_\_ of this Preliminary Prospectus. The historical financial condition, results of operations and cash flows of \_\_\_\_\_\_\_\_\_\_\_\_\_\_ are not a guarantee of its future operating and financial performance.

|  |  |  |
| --- | --- | --- |
|  | **For the years ended \_\_\_\_\_\_\_\_\_\_\_\_,** | **For the \_\_\_\_\_\_ months ended \_\_\_\_\_\_\_\_\_\_\_,** |
|  | **20\_\_\_\_** | **20\_\_\_\_** | **20\_\_\_\_** | **20\_\_\_\_** | **20\_\_\_\_\_** |
|  | **(Audited)** | **(Audited)** |
|  | **(in millions except per share figures or where otherwise indicated)** |
| **Consolidated Statements of Income Data** |  |  |  |  |  |

|  |  |  |
| --- | --- | --- |
|  | As of the years ended  | As of the \_\_\_\_\_\_\_ months ended |
|  | **(Audited)** | **(Audited)** |
|  | **20\_\_\_\_\_\_** | **20\_\_\_\_\_\_** | **20\_\_\_\_\_\_** | **20\_\_\_\_\_\_** |
| **Consolidated Statements of Financial** **Position Data** |  |  |  |  |

|  |  |  |
| --- | --- | --- |
|  | **For the years ended December 31,** | **For the \_\_\_\_\_ months ended ,** |
|  | **20\_\_\_** | **20\_\_\_\_** | **20\_\_\_\_** | **20\_\_\_** |
|  | **(Audited)** | **(Audited)** |
| **Cash Flow Data** |  |  |  |  |
|  |  |  |  |  |

# Information on Independent Accountant and other Related Matters

### External Audit Fees and Services

1. The External Auditor has rendered (select all that apply):

|  |  |
| --- | --- |
|  | audit of the registrant’s annual financial statements or services that are normally provided by the external auditor in connection with statutory and regulatory filings or engagements for those fiscal years |
|  | Other assurance and related services that are reasonable related to the performance of the audit or review of the registrant’s financial statements. |
|  | The audit committee has approved the above mentioned services |

1. The aggregate fees billed are shown below

|  |  |  |
| --- | --- | --- |
| Year | 20\_\_ | 20\_\_ |
| Audit Fees |  |  |
| Tax Fees |  |  |
| All Other Fees |  |  |

### Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

1. The Issuer has no disagreement with its external auditor on any matter regarding (select all that apply):

|  |  |
| --- | --- |
|  | Accounting principles or practices |
|  | Financial statement disclosures |
|  | Auditing scope or procedure |
| (a) If during the registrant's two most recent fiscal years or any subsequent interim period, an independent accountant who was previously engaged as the principal accountant to audit the registrant's financial statements, or an independent accountant who was previously engaged to audit a significant subsidiary, ceased performing services for registrant, disclose the name of the previous accountant or the handling partner in case of a firm, reason/s for the cessation of service and the date of his resignation, dismissal or cessation of performing services for registrant.(b) Describe disagreements, if there were any, with the former accountant on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure which, if not resolved to the satisfaction of the former accountant, would have caused it to make reference to the subject matter of the disagreement(s) in connection with its report.(c) If there were any disagreements as described in subparagraph (2), the registrant shall request the former accountant to furnish the registrant with a letter addressed to the Commission stating whether it agrees with the statements made by the registrant and, if not, stating the respects in which it does not agree. The registrant shall file the former accountant's letter as an exhibit to the report or registration statement containing this disclosure |

### Taxation

1. Describe any material tax consequences to Investors in this Offering:

|  |
| --- |
|  |

# INDEPENDENT AUDITORS AND COUNSELS

### Tax and Legal Matters

All legal opinions/matters in connection with the issuance of each Offer will be passed upon by \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ for the Company. \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ have no direct interest in the Company.

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ may from time to time be engaged to advise in the transactions of the Company and perform legal services on the basis that \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ provide such services to its other clients.

### Independent Auditors

The consolidated financial statements of the Company as at and for the years ended have been audited by \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_, independent auditors, in accordance with Philippine Standards on Auditing as set forth in their report thereon appearing elsewhere in this Prospectus.

The Audit Committee of the Company, reviews and monitors, among others, the integrity of all financial reports and ensures compliance with both internal financial management manual and pertinent accounting standards, including regulatory requirements. The Audit Committee also performs the following duties and responsibilities relating to the services of the Company’s external auditors:

|  |
| --- |
|  |

There is no arrangement that experts and independent counsels will receive a direct or indirect interest in the Issuer or was a promoter, underwriter, voting trustee, director, officer, or employee of the Issuer.

# OTHER MATERIAL FACTORS

Describe any other material factors that will or could affect the Issuer or its business or which are necessary to make any other information in this Statement not misleading or incomplete.